Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Novartis ( (NVS) ) has provided an update.
On July 17, 2025, Novartis reported strong financial results for the second quarter of 2025, with net sales increasing by 11% and core operating income rising by 21%. The growth was driven by successful performances of key products like Kisqali, Entresto, and Pluvicto. The company also achieved significant innovation milestones, including positive Phase III study results for Pluvicto and FDA approval for Vanrafia. Novartis raised its full-year 2025 core operating income guidance and announced a share buyback program of up to USD 10 billion, reflecting confidence in its long-term growth strategy.
The most recent analyst rating on (NVS) stock is a Hold with a $123.50 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Novartis receives a strong overall score due to its solid financial performance and positive earnings call. The company’s profitability metrics and cash flow management are impressive, supporting sustainable growth. The bullish technical trend is tempered by potential overbought signals. Valuation is fair, providing a reasonable entry point for investors. Positive earnings call guidance and sentiment further bolster the stock’s attractiveness, despite some operational challenges.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis is a leading innovative medicines company focusing on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. The company prioritizes investment in emerging platforms such as gene and cell therapy, radioligand therapy, and xRNA, with a market focus on the US, China, Germany, and Japan.
Average Trading Volume: 1,575,411
Technical Sentiment Signal: Buy
Current Market Cap: $228.1B
See more insights into NVS stock on TipRanks’ Stock Analysis page.